Navigation Links
Abbott Completes Acquisition of Facet Biotech
Date:4/21/2010

ABBOTT PARK, Ill., April 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech Corporation, strengthening its pharmaceutical pipeline in immunology and oncology.

The acquisition provides Abbott with a promising biologic intended to treat multiple sclerosis (MS) and compounds that complement its existing diverse oncology program.  The new Abbott compounds include daclizumab – a Phase II investigational biologic intended to treat multiple sclerosis that is expected to move into Phase III development in the second quarter 2010 – and oncology compounds in early- to mid-stage development that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia.

"Facet's depth of biologics experience and sophisticated antibody engineering platforms complement Abbott's current R&D programs in oncology, immunology and other therapeutic areas," said John Leonard, M.D., senior vice president, global pharmaceutical research and development, Abbott.

The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common stock not tendered in the cash tender offer (other than those as to which holders properly exercise dissenters' rights) were converted into the right to receive $27 per share in cash, without interest and subject to any required withholding taxes.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... YORK , Feb. 27, 2017 /PRNewswire/ ... Michael P. Vallely , MBBS, PhD, FRACS, of  ... University of Sydney will be published ...  Journal of the American College of Cardiology ... "no-touch" beating heart bypass surgery technique (anOPCABG) ...
(Date:2/27/2017)... Feb. 27, 2017  International Biophysics Corporation, a global medical ... today announced a 34% revenue growth in 2016 when compared ... unit sales.  This growth was fueled by its AffloVest® sales ... to the expansion of its global sales of surgical product ... CEO, "As we enter our 25 th year in ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had ... his impoverished upbringing and life experiences could have led him down a much different ... Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. ... studying to become a nun. Now, she writes about God, when she isn’t swimming as ... BC and AD, Here is BS! (Before Satan),” she offers a comedic look at the ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
Breaking Medicine News(10 mins):